Korean Journal of Urological Oncology  2017;15(2):59-65

doi:10.22465/kjuo.2017.15.2.59

Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer.

Dong Hoon LEE 1 ; Jung Ho KIM ; Won Ik SEO ; Jong Kil NAM ; Tae Nam KIM ; Cheol Kyu OH ; Soo Dong KIM ; Sung Woo PARK ; Jae Sung CHUNG ; Sang Hyun PARK ; Wan LEE ; Gyung Tak SUNG ; Moon Kee CHUNG ; Jae Il CHUNG

Affiliations

+expand

Keywords

Androgen deprivation therapy; Castration-resistant prostate cancer; Docetaxel chemotherapy

Country

Republic of Korea

Language

English

Abstract

PURPOSE: This study compared the oncologic results of docetaxel chemotherapy (DOC) in castration-resistant prostate cancer (CRPC) according to continuous addition of androgen deprivation therapy (ADT) during chemotherapy. MATERIALS AND METHODS: We retrospectively reviewed the medical records of 106 patients who received DOC in 6 medical institutes. Among them, 72 patients had a complete medical record: 28 patients with ADT (DOC+continuous ADT group) and 44 without ADT (DOC only group). We compared the progression-free survival of these groups after DOC. RESULTS: Docetaxel was administered an average of 28 months after primary ADT as the first treatment. A median number of 6 cycles of DOC was administered in both groups. In the DOC+continuous ADT group, orchiectomy was performed in 18 patients and luteinizing hormone-releasing hormone agonist was injected in 10 patients. During DOC treatment, prostate-specific antigen (PSA) progression-free survival was statistically different (6.0±4.75 months in DOC+continuous ADT group vs. 4.8±3.2 months in DOC only group, p=0.024), whereas radiologic progression-free survival was not statistically different (5.0±3.12 months in DOC+continuous ADT group vs. 5.0±2.79 months in DOC only group, p=0.387). CONCLUSIONS: In our cohort, continuous addition of ADT showed a significant benefit in PSA progression-free survival during DOC in CRPC patients. Further prospective studies are needed to confirm these observations.